Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Videos|November 7, 2021
Expert Discusses Limitations of Vascular Calcification Treatments
Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how pharmacists are limited to traditional treatment of chronic kidney disease, while waiting for new treatment options.
Advertisement
In a Pharmacy Times® interview, Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, about his ASN 2021 Kidney Week presentation on the prevention of vascular calcification in chronic kidney disease (CKD).
He discussed how pharmacists are limited to traditional treatment of CKD, while waiting for new treatment options.
Advertisement
Related to this article
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Advertisement
Advertisement